For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
An Olympus Corp. subsidiary pleaded guilty and agreed to pay $85 million to resolve charges of failure to file reports with U.S. regulators regarding infections connected to its duodenoscopes while continuing to sell the medical devices used to view the gastrointestinal tract.
2018 was the year of the consumer, and there is no sign of a change any time soon.
Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.
Medtronic will pay a total of nearly $51 million to resolve three legal claims against Covidien Plc and ev3 Inc., two companies that are now part of the Ireland-based medtech company. Medtronic itself had no role in the wrongdoings that resulted in the multi-million fines.
Eight medical device makers – including a startup that uses virtual reality to treat chronic pain – topped an innovation contest aimed at addressing the opioid crisis, the U.S. FDA said.
Healthcare stocks rallied with U.S. health insurers reaching record highs as results of the 2018 mid-term elections were seen reducing the likelihood of action to cut medical costs and programs in the world’s biggest and most profitable market.
Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results
Abbott announced today that the U.S. Food and Drug Administration cleared the company’s next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing.
Johnson & Johnson reported slightly better-than-expected third-quarter 2018 profit and raised the company’s full-year forecast.
Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.